Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma

NCT03974854 | Terminated Phase 2 DMC

• 1 other identifier: P/2018/395
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 5

Brief Summary

Current standard of care for patients with metastatic Pancreatic Ductal AdenoCarcinoma (PDAC) is chemotherapy, preferential regimen being FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin). Due to more hematologic (neutropenia) and gastrointestinal toxicities, FOLFIRINOX is only administered in fit patients (age \< 75 years, ECOG Performance status 0-1, and bilirubin \< 1.5 ULN). However, elderly or frail patients represent more than half of patients with PDAC and are treated with gemcitabine monochemotherapy. Maintaining more than one drug (polychemotherapy) may improve survival and quality of life in this population. ALIX is a non-comparative randomized 2:1 phase II study. This study will assess the efficacy and safety of the polychemotherapy with XELOXIRI-3 versus gemcitabine as first-line chemotherapy in elderly or frail patients with locally advanced or metastatic PDAC.

Conditions

Metastatic Pancreatic Adenocarcinoma

Outcome Measures

Primary Outcomes (1)

• 6 months Progression-Free Survival (PFS) rate

  6 months after the date of initiation of treatment (1st day of 1st cycle of chemotherapy)

Study Arms (2)

Arm A: XELOXIRI-3

EXPERIMENTAL

capecitabine 625 mg/m2 twice daily on days 1-7 oxaliplatine 85 mg/m2 on Day 1 irinotecan 90 mg/m2 on Day 3, every 14 days

Drug: XELOXIRI-3

Arm B: Gemcitabine

ACTIVE COMPARATOR

1000 mg / m2 on D1, D8 and D15, every 28 days

Drug: Gemcitabine

Interventions

XELOXIRI-3 DRUG

chemotherapy with XELOXIRI-3 regimen

Also known as: Capecitabine, Oxaliplatine, Irinotecan

Arm A: XELOXIRI-3

Gemcitabine DRUG

chemotherapy with Gemcitabine regimen

Arm B: Gemcitabine

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Histologically proven pancreatic ductal adenocarcinoma
• Locally Advanced or metastatic disease
• Measurable disease according to RECIST v1.1 criteria
• Age ≥ 75 years;
• OR age between 65 and 75 years AND with at least one frailty contraindication to the administration of chemotherapy with FOLFIRINOX:
• Eastern Cooperative Oncology Group Performance status (ECOG-PS) 2
• Total serum bilirubin \> 1.5 ULN (biliary drainage allowed)
• Clinico-biological frailty criteria:
• weight loss \> 10% in 6 months or \> 5% in 1 month
• or body mass index (BMI) ≤ 21
• or serum albumin \< 30 g/L
• or ADL (Activities of Daily Living) score \< 6
• Eligible for gemcitabine as first-line chemotherapy
• Registration in a national health care system
• Written informed consent obtained from the patient prior to performing any protocol-related procedures

You may not qualify if:

• Age \< 65 years
• Localized non-metastatic cancer
• ECOG-PS 3-4
• Previous treatment For advanced stage (locally advanced or metastatic): chemotherapy, radiochemotherapy; For localized stage: FOLFIRINOX chemotherapy (neoadjuvant or adjuvant); adjuvant chemotherapy with gemcitabine before relapse is permitted (provide it has been administered more than 6 months before)
• Uncontrolled intercurrent cardiovascular disease
• Known or suspected allergy or hypersensitivity to any of the study drugs (capecitabine, oxaliplatin, irinotecan, gemcitabine)
• Bowel obstruction or sub-obstruction or impossible oral treatment
• Prior peripheral neuropathy of grade ≥ 2
• Known complete dihydropyrimidine dehydrogenase (DPD) or UDP-glycosyltransferase 1 polypeptide A1 (UGT1A1) deficiency
• Inadequate hematological, hepatic, and renal functions
• Psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs (Adverse Events) or compromise the ability of the patient to give written informed consent
• Tutelage or guardianship
• Diagnosis of any second malignancy within the last 2 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri
• Current participation in another clinical trial using therapeutic experimental agents

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Besancon: lead

Study Sites (5)

University Hospital of Besançon

Besançon, France

Location

Hôpital Nord Franche-Comté

Montbéliard, France

Location

CH Mulhouse

Mulhouse, France

Location

CHU Nancy

Nancy, France

Location

CHU Reims

Reims, France

Location

MeSH Terms

Interventions

Capecitabine; Oxaliplatin; Irinotecan; Gemcitabine

Intervention Hierarchy (Ancestors)

Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Fluorouracil; Uracil; Pyrimidinones; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Coordination Complexes; Organic Chemicals; Camptothecin; Alkaloids

Study Officials

• Angélique VIENOT, Dr

  University Hospital of Besançon

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 3, 2019
• First Posted: June 5, 2019
• Study Start: July 8, 2019
• Primary Completion: August 1, 2023
• Study Completion: February 1, 2024
• Last Updated: December 27, 2024

Record last verified: 2024-12

Data Sharing

• IPD Sharing: Will not share

Locations

FR (5)